Choon Yong Loo Buys Handful Of Shares In Raffles Medical Group
Choon Yong Loo Buys Handful Of Shares In Raffles Medical Group
Those following along with Raffles Medical Group Ltd (SGX:BSL) will no doubt be intrigued by the recent purchase of shares by Choon Yong Loo, Executive Chairman & CEO of the company, who spent a stonking S$1.5m on stock at an average price of S$0.89. While that only increased their holding size by 0.7%, it is still a big swing by our standards.
萊佛士醫療集團有限公司(新加坡證券交易所股票代碼:BSL)的追隨者無疑會對該公司執行董事長兼首席執行官Choon Yong Loo最近收購的股票感興趣,他在股票上花費了驚人的150萬新元,平均價格爲0.89新元。儘管這僅使他們的持股規模增加了0.7%,但按照我們的標準,這仍然是一個很大的波動。
Raffles Medical Group Insider Transactions Over The Last Year
萊佛士醫療集團去年的內幕交易
Notably, that recent purchase by Executive Chairman & CEO Choon Yong Loo was not the only time they bought Raffles Medical Group shares this year. Earlier in the year, they paid S$1.03 per share in a S$3.6m purchase. That means that an insider was happy to buy shares at above the current price of S$0.91. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Choon Yong Loo was the only individual insider to buy shares in the last twelve months.
值得注意的是,執行董事長兼首席執行官Choon Yong Loo最近的收購併不是他們今年唯一一次購買萊佛士醫療集團的股票。今年早些時候,他們每股支付了1.03新元的360萬新元的收購。這意味着內部人士樂於以高於當前0.91新元的價格購買股票。他們很可能會後悔這次收購,但他們更有可能看好該公司。對我們來說,考慮內部人士爲股票支付的價格非常重要。通常,當內部人士以高於當前的價格購買股票時,我們對股票的看法會更加樂觀,因爲這表明他們認爲股票即使價格更高,也物有所值。Choon Yong Loo是過去十二個月中唯一購買股票的內部人士。
Choon Yong Loo bought a total of 41.10m shares over the year at an average price of S$0.99. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Choon Yong Loo全年共購買了4110萬股股票,平均價格爲0.99新元。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
內部人士總是會買入很多股票。如果你喜歡投資鮮爲人知的公司,你可以看看這份免費的公司清單。(提示:內部人士一直在購買它們)。
Insider Ownership
內部所有權
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Raffles Medical Group insiders own 15% of the company, worth about S$253m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。較高的內部所有權通常會使公司領導層更加關注股東的利益。很高興看到萊佛士醫療集團內部人士擁有該公司15%的股份,價值約2.53億新元。大多數股東會很高興看到這種內部所有權,因爲這表明管理層的激勵措施與其他股東非常一致。
So What Do The Raffles Medical Group Insider Transactions Indicate?
那麼,萊佛士醫療集團的內幕交易表明了什麼?
It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. When combined with notable insider ownership, these factors suggest Raffles Medical Group insiders are well aligned, and quite possibly think the share price is too low. One for the watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Raffles Medical Group. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Raffles Medical Group.
看到最近的內幕收購無疑是積極的。長期的內幕交易也給了我們信心。再加上顯著的內部所有權,這些因素表明萊佛士醫療集團內部人士意見一致,很可能認爲股價過低。至少有一張是監視列表的!除了了解正在進行的內幕交易外,確定萊佛士醫療集團面臨的風險也是有益的。爲了幫助解決這個問題,我們發現了一個警告信號,你應該仔細檢查一下,以更好地了解萊佛士醫療集團。
Of course Raffles Medical Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,萊佛士醫療集團可能不是最好的買入股票。因此,您可能希望看到這個免費的高質量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。